Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
Cancer Research and Treatment. 2019;51(1):158-168 
EGFR mutational status in lung adenocarcinoma: Staging implications or continuous evolution?
The Journal of Thoracic and Cardiovascular Surgery. 2017;154(5):1766-1767
16 EGFR mutational analysis for adenocarcinoma of the lung; outcome by mutation since the introduction of routine molecular testing in one cancer network
Lung Cancer. 2013;79:S6
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases. 2019;82(1):62
Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
Radiology and Oncology. 2014;48(2):173-183
Non–Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non–Small-cell Lung Cancer Favor Adenocarcinoma
Clinical Lung Cancer. 2017;18(3):316-323.e1
Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
Clinical Lung Cancer. 2018;19(2):105-114
Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients
Lung Cancer. 2018;119:120-126
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
Lung Cancer: Targets and Therapy. 2017;Volume 8:21-30
EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
OncoTargets and Therapy. 2015;3017